Amanda Kahn, dubbed the "Peptide Princess of Park Avenue," runs a concierge longevity practice on Manhattan's Upper East Side where $50,000 annual fees buy personalized peptide regimens. Peptides — short amino acid chains that signal cellular repair — have moved beyond FDA-approved drugs like insulin and Ozempic into experimental "stacks" combining compounds such as BPC-157 and TB-500 for tissue repair, GHK-Cu for collagen, and NAD+ for energy.\n\nPatients like jewellery designer Jennifer Fisher credit peptides with reversing hair loss from Hashimoto's, while celebrity facialist Iván Pol regained his "twenties body" via daily injections. Kahn's roster is 60% women, 40% men, ranging from 24-year-olds to former athletes.

Aesthetics draw them in; longevity keeps them.\n\nRegulation remains murky: some peptides lack FDA approval for human use, though doctors can prescribe off-label. The FDA cracked down on unapproved peptide marketing in 2024. Meanwhile, the global peptide therapeutics market hit $140.86bn in 2025, projected to reach $163.98bn this year.

Online grey markets selling unvetted semaglutide and tirzepatide from foreign factories pose safety risks.